Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients

NCT02986178 is registered in ClinicalTrials.gov with Istari Oncology, Inc. as lead sponsor.

NCT NCT02986178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02986178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
Lead sponsor
Istari Oncology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2017
Completion date
February 3, 2023
Enrollment
121 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

malignant glioma